Pivotal trial results for upadacitinib (Rinvoq) in adolescents and adults with moderate-to-severe atopic dermatitis were published on 2021-01-01. The publication detailed findings from two replicate studies, Measure Up 1 and Measure Up 2, which demonstrated the efficacy of once-daily upadacitinib compared to placebo.
Background
Upadacitinib (Rinvoq) is an oral medication developed for inflammatory conditions. These published results specifically address its use in adolescents and adults with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. Atopic dermatitis is characterized by intense itching, dry skin, and eczematous lesions, significantly impacting patients' quality of life. The studies aimed to evaluate upadacitinib's potential to provide therapeutic benefit in this patient population.
Trial design
The published findings originate from two pivotal, replicate studies, designated as Measure Up 1 and Measure Up 2. These trials were designed to evaluate once-daily upadacitinib against placebo in adolescents and adults diagnosed with moderate-to-severe atopic dermatitis. The primary objective of these studies was to assess the efficacy and safety profile of upadacitinib, comparing its therapeutic effects to those observed in the placebo arm.
What this means
The publication of these pivotal trial results marks a significant development for the treatment landscape of moderate-to-severe atopic dermatitis. For clinicians, these findings provide evidence supporting the potential of upadacitinib as an effective treatment option for their adolescent and adult patients. For researchers, these detailed results contribute to the growing body of knowledge regarding targeted therapies for inflammatory skin diseases. Patient advocates will view this as a positive step towards expanding available treatment choices for a condition that significantly impacts quality of life.
Source
The information regarding these pivotal trial results was published on 2021-01-01 in a document indexed by PubMed. The publication detailed the findings from the Measure Up 1 and Measure Up 2 studies, which are accessible via the PubMed host at pubmed.ncbi.nlm.nih.gov.